Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Baer

Showing results (511-520 of 542) with videos related to

Pageof 55
Sort By:
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase ActivatorsXiaohui Du, Ronald J Hinklin, Yumei Xiong, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Pageof 55

Showing results (511-520 of 542) with videos related to

Sort By:
Pageof 55
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase ActivatorsXiaohui Du, Ronald J Hinklin, Yumei Xiong, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Pageof 55